Advertisement

Topics

Latest "Rosuvastatin Placebo Critically" News Stories

23:00 EST 18th January 2019 | BioPortfolio

Here are the most relevant search results for "Rosuvastatin Placebo Critically" found in our extensive news archives from over 250 global news sources.

More Information about Rosuvastatin Placebo Critically on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Rosuvastatin Placebo Critically for you to read. Along with our medical data and news we also list Rosuvastatin Placebo Critically Clinical Trials, which are updated daily. BioPortfolio also has a large database of Rosuvastatin Placebo Critically Companies for you to search.

Showing "Rosuvastatin Placebo Critically" News Articles 1–25 of 1,200+

Friday 18th January 2019

[Corrections] Correction to Lancet Neurol 2019; 18: 145–54

LeWitt PA, Hauser RA, Pahwa R, et al, on behalf of the SPAN-PD Study Investigators. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019; 18: 145–54—In this Article, CVT-301 was incorrectly spelled in some instances in the Summary an...


Thursday 17th January 2019

Tinkering with public debt we doom innovation and growth

(Bocconi University) New research by Bocconi University's Mariano Max Croce and colleagues finds that public debt is bad for growth also because it hinders innovative firms' investment. «By affecting their cost of capital, movements in government debt impact firms' investment and, critically, innovation decisions», Prof. Croce says. The net result is a GDP growth drop in 4/5 years, when the lack...

Researchers identify specific cognitive deficits in individuals with spinal cord injury

(Kessler Foundation) "People often focus on mobility impairments associated with SCI; however, addressing cognitive deficits in this population is also critically important," said co-author Dr. Dyson-Hudson, director of SCI Research, and director of the Northern New Jersey SCI Model System. "Future research needs to be based on broader measures of neuropsychological function. Identifying modifiabl...


Servier and Taiho Oncology Present Latest LONSURF® (trifluridine/tipiracil) Data at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today that the safety and efficacy data in the gastrectomy patient subgroup of the global Phase III trial TAGS evaluating LONSURF® (trifluridine/tipiracil, TAS-102) in patients with metastatic gastric cancer (mGC) are consistent with the over...

Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA™ (levodopa inhalation powder)

SPAN℠-PD, the efficacy and safety study of INBRIJA (CVT-301), showed significant improvement in motor function during OFF periods in people with Parkinson’s on a carbidopa/levodopa regimen INBRIJA was approved in the U.S. in Dec. 2018 and is expected to be available by prescription in Q1 2019 Acorda Therapeutics...

Ironshore Pharmaceuticals Announces Appointment of Dr. Lewis Warrington as Vice President / Head of Medical Affairs

Ironshore Pharmaceuticals, Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. (“Highland”) and a leader in the commercialization of novel treatments for

Gender difference in the effects of cacao polyphenols on blood pressure and glucose/lipid metabolism in prediabetic subjects: a double-blinded, randomized, placebo-controlled crossover trial

Tricida Announces Hiring of Susannah Cantrell, Ph.D., as Chief Commercial Officer

Tricida, Inc. (Nasdaq: TCDA), today announced the hiring of Susannah Cantrell, Ph.D., as Chief Commercial Officer and Senior Vice President. Dr. Cantrell will lead Tricida’s commercial planning and operations functions. “Susannah brings a breadth and depth of strategic and operational experience to Tricida that we believe will enable us t...

Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy

Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced the completion of patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, ...

HPV vaccination rates remain critically low among younger adolescents in the U.S.

Only about 16 percent of U.S. adolescents have been fully vaccinated against human papillomavirus (HPV) by the time they turn 13, despite national recommendations that call for vaccination at 11 to 12 years of age. The new findings highlight the need for stronger efforts to encourage HPV vaccination and to improve immunization rates in this key age group.

Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Gastric Cancer

SUZHOU, China, Jan. 17, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced today that the first patient has been dosed in a phase III clinical trial (ORIENT-16) that is to evaluate Tyvyt® (fully human anti-PD-1 therapeutic monoclonal antibody, generic name: sintilimab...

Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019

Safety, tolerability and pharmacodynamics of BoNT-E demonstrated in Phase I study1 Regulatory News: Results of the first in-human study of a recombinant neurotoxin are being presented at the TOXINS International Conference in Copenhagen. Ipsen’s recombinant BoNT serotype E (rBoNT-E) was investigated in a phase I study that demonstrate...

Wednesday 16th January 2019

HPV vaccination rates remain critically low among younger adolescents in the US

(Infectious Diseases Society of America) Only about 16 percent of US adolescents have been fully vaccinated against human papillomavirus (HPV) by the time they turn 13, despite national recommendations that call for vaccination at 11 to 12 years of age. Published in the Journal of Infectious Diseases, the new findings highlight the need for stronger efforts to encourage HPV vaccination and to impr...

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerMONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer, Published online: 17 January 2019; doi:10.1038/s41523-018-0097-zPatients with the most common form of breast cancer stand to benefit from taking a drug that blocks two cell cycle–regulating protei...

vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study

Results Found TTP399 Demonstrated a Statistically Significant Improvement in HbA1c Compared to Placebo without Hypoglycemia or Hyperlipidemia vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small ...

Pediatric Alliance Joins Allegheny Health Network - Region’s Largest Independent Pediatrics Group Employs 60+ Caregivers at 17 Practice Locations across Western PA

Pediatric Alliance, one of western Pennsylvania’s largest independent pediatric physician groups, has joined Allegheny Health Network (AHN), officials of both organizations announced today. PITTSBURGH (PRWEB) January 16, 2019 Pediatric Alliance, one of western Pennsylvania’s largest independent pediatric physician groups, has joined Allegheny Health Network (AHN), officials of both organizati...

Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease

Phase 3 SPARTAN data served as basis for approval, which showed apalutamide decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years1 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted...

Aradigm Announces Detailed Third Party Evaluation Results for Apulmiq (FDA)/Linhaliq (EMA)

Aradigm Corporation (OTCQB: ARDM) ("Aradigm" or the "Company") today announced specific, detailed results of an independent third party evaluation (TPE) of the Phase 3 clinical trial results for Apulmiq. As previously reported, Aradigm received a Complete Response Letter (CRL) on 26 January 2018, from the US Food and Drug Administrati...

Choice of Fluids in Critically Ill Patients

This review provides current guidance on fluid management of critically ill patients in specific clinical settings including sepsis, ARDS, trauma, AKI, and more. BMC Anesthesiology

A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial

Tuesday 15th January 2019

New JAMA Report, Initiated by AAAAI and Others, Provides Recommendations for Evaluating and Managing Penicillin Allergy

Verifying the accuracy of a documented penicillin allergy can improve treatment outcomes, avoid spread of antibiotic resistance MILWAUKEE (PRWEB) January 15, 2019 While more than 32 million individuals in the United States have a documented penicillin allergy in their medical record, studies have shown that over 95% can actually be treated safely with this class of antibiotics, improving treatmen...

Early Treatment Shows Lower Risk to Secondary Progressive MS

(MedPage Today) -- All therapies best placebo, prospective study shows

MedMates Rebrands as RI Bio, Brings New Resources, Partnerships and Research to Rhode Island

RI Bio’s Momentum Will Significantly Boost Growing Life Sciences Community Rhode Island Bio (RI Bio), southeastern New England’s leading life sciences industry group, has announced the launch of its new brand, the availability of its full suite of member services and a host of significant organizational developments that will impact the life ...

Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today announced that the National Medical Products Administration (NMPA) approved the marketing application for LINZESS® (linaclotide) for adults with irritable bowel syndrome with

Verona's shares drop 34% on Phase 2 failure of nebulised ensifentrine in COPD

Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised ensifentrine, known as RPL554, in combination with Boehringer’s Stiolto Respimat (tiotropium/olodaterol) in the treatment of chronic obstructive pulmonary disease (COPD). Share value fell by as much as 34% when news broke that the therapy failed to meet statistical significance in its primary endpoint of impr...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks